Palatin Technologies (PTN)

$0.22 -0.03 (-10.57%)
Market Cap 5.72M
Revenue (ttm) 4.49M
Net Income (ttm) -29.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -662.36%
Debt to Equity Ratio 0.00
Volume 13,128,500
Avg Vol 2,698,744
Day's Range N/A - N/A
Shares Out 26.01M
Stochastic %K 16%
Beta 0.89
Analysts Strong Sell
Price Target $7.00

Latest News on PTN

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Apr 17, 2025, 7:30 AM EDT - 2 days ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Appeals NYSE American Notice of Delisting

Apr 14, 2025, 7:00 AM EDT - 5 days ago

Palatin Appeals NYSE American Notice of Delisting

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

Apr 10, 2025, 4:15 PM EDT - 9 days ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Apr 10, 2025, 4:01 PM EDT - 9 days ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Apr 10, 2025, 7:30 AM EDT - 9 days ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Mar 31, 2025, 7:30 AM EDT - 19 days ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Mar 28, 2025, 7:30 AM EDT - 22 days ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Mar 25, 2025, 7:30 AM EDT - 25 days ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Feb 15, 2025, 5:41 AM EST - 2 months ago

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Feb 13, 2025, 7:30 AM EST - 2 months ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Feb 10, 2025, 4:00 PM EST - 2 months ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Feb 7, 2025, 8:00 AM EST - 2 months ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Feb 6, 2025, 7:30 AM EST - 2 months ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Jan 28, 2025, 7:30 AM EST - 2 months ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Dec 19, 2024, 7:30 AM EST - 4 months ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Dec 16, 2024, 7:30 AM EST - 4 months ago

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Nov 25, 2024, 7:30 AM EST - 5 months ago

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Nov 14, 2024, 12:49 PM EST - 5 months ago

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Nov 14, 2024, 7:30 AM EST - 5 months ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Nov 8, 2024, 9:57 AM EST - 5 months ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Nov 4, 2024, 7:30 AM EST - 5 months ago

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Oct 31, 2024, 7:30 AM EDT - 6 months ago

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Oct 24, 2024, 7:30 AM EDT - 6 months ago

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Oct 23, 2024, 7:30 AM EDT - 6 months ago

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Palatin Receives Notice of Non-Compliance from NYSE American

Oct 7, 2024, 4:15 PM EDT - 6 months ago

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Oct 1, 2024, 2:55 PM EDT - 7 months ago

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Oct 1, 2024, 7:30 AM EDT - 7 months ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Sep 26, 2024, 7:30 AM EDT - 7 months ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Sep 9, 2024, 7:30 AM EDT - 7 months ago

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Aug 28, 2024, 7:30 AM EDT - 8 months ago

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Aug 22, 2024, 7:30 AM EDT - 8 months ago

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Jun 21, 2024, 8:00 AM EDT - 10 months ago

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

Jun 20, 2024, 7:30 AM EDT - 10 months ago

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

Jun 12, 2024, 7:30 AM EDT - 11 months ago

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

May 15, 2024, 7:30 AM EDT - 1 year ago

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

May 9, 2024, 7:30 AM EDT - 1 year ago

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

May 2, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Apr 8, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Feb 28, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript

Feb 15, 2024, 2:49 PM EST - 1 year ago

Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Feb 15, 2024, 7:30 AM EST - 1 year ago

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

Feb 9, 2024, 7:30 AM EST - 1 year ago

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Feb 5, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Announces Closing of $10 Million Registered Direct Offering

Feb 1, 2024, 4:00 PM EST - 1 year ago

Palatin Announces Closing of $10 Million Registered Direct Offering

Palatin Announces $10 Million Registered Direct Offering

Jan 30, 2024, 8:00 AM EST - 1 year ago

Palatin Announces $10 Million Registered Direct Offering

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

Jan 8, 2024, 10:33 AM EST - 1 year ago

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Jan 3, 2024, 8:00 AM EST - 1 year ago

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million

Dec 20, 2023, 7:30 AM EST - 1 year ago

Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million

Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

Dec 18, 2023, 4:15 PM EST - 1 year ago

Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American